免疫疗法
髓系白血病
嵌合抗原受体
医学
抗原
免疫系统
免疫检查点
癌症免疫疗法
免疫学
癌症研究
作者
Cecilia Restelli,Marco Ruella,Luca Paruzzo,Corrado Tarella,Pier Giuseppe Pelicci,Emanuela Colombo
出处
期刊:Blood cancer discovery
[American Association for Cancer Research]
日期:2024-06-21
卷期号:5 (4): 234-248
被引量:2
标识
DOI:10.1158/2643-3230.bcd-23-0202
摘要
Despite advancements, acute myeloid leukemia (AML) remains unconquered by current therapies. Evidence of immune evasion during AML progression, such as HLA loss and T-cell exhaustion, suggests that antileukemic immune responses contribute to disease control and could be harnessed by immunotherapy. In this review, we discuss a spectrum of AML immunotherapy targets, encompassing cancer cell-intrinsic and surface antigens as well as targeting in the leukemic milieu, and how they can be tailored for personalized approaches. These targets are overviewed across major immunotherapy modalities applied to AML: immune checkpoint inhibitors, antibody-drug conjugates, therapeutic vaccines, bispecific/trispecific antibodies, and chimeric antigen receptor (CAR)-T and CAR-NK cells. Significance: Immune therapies in AML treatment show evolving promise. Ongoing research aims to customize approaches for varied patient profiles and clinical scenarios. This review covers immune surveillance mechanisms, therapy options like checkpoint inhibitors, antibodies, CAR-T/NK cells, and vaccines, as well as resistance mechanisms and microenvironment considerations.
科研通智能强力驱动
Strongly Powered by AbleSci AI